is a chronic autoimmune disease characterized by a diminished number of (functional) acetylcholine receptors (AChRs) at the neuromuscular junction. In the majority of patients with generalized myasthenia gravis, antibodies against the AChR are detectable in the serum. These antibodies cause a decrease in functional AChR in three different ways: first, an increased turnover of AChR, induced by the antibodies; second, focal lysis of the postsynaptic membrane by complement activation; and third, pharmacological blockade of the AChR. 1,2
As a result, the sensitivity to nondepolarizing neuromuscular blocking agents (NMBAs) is increased; thus, lower doses of NMBAs are required to obtain a certain degree of neuromuscular block. Even after an equipotent dose, the time course of effect is prolonged. 3,4
There is currently no pharmacokinetic–pharmacodynamic model that will explain the typical combination of increased sensitivity and prolonged time course of NMBAs as found in myasthenic patients.
The most used pharmacokinetic–pharmacodynamic model is the Sheiner link model. 5
In most situations, it is an adequate model to describe the time course of effect of NMBAs. In simulations, the pharmacokinetic–pharmacodynamic model proposed by Sheiner may predict the higher sensitivity to and the longer recovery time of NMBAs in myasthenic patients based on a lower EC50
and γ. The Sheiner model, however, gives no insight as to why these parameters are changed in this group of patients. This model does not take into account the number of AChRs, and the decrease in the effective dose needed to obtain a 90% neuromuscular block (ED90
) in myasthenic patients can only be explained by a decreased effective concentration that corresponds with 50% neuromuscular block (EC50
), which does not alter the time course of effect of neuromuscular blocking drugs. Donati 6
proposed a model taking into account the AChR concentration at the neuromuscular junction. This model does not predict the alterations observed in myasthenic patients, either; it predicts a slightly decreased ED90
when the AChR concentration is decreased, 7
while the actual ED90
decreases by more than 50% in myasthenic patients. 8
The predicted interval 25–75% (time from 25% twitch depression to 75%) is decreased in sensitive patients, which is contrary to the increased interval 25–75% seen in myasthenic patients.
We developed a novel physiologically based pharmacokinetic–pharmacodynamic model assuming that the contractile force of a muscle after supramaximal stimulation is related to the concentration of free AChRs, i.e., not blocked by NMBAs or antibodies against the AChR. This model predicts an increased potency and a prolonged duration of action of NMBAs in case of a reduced number of AChRs at the neuromuscular junction, in line with the changes observed in myasthenia gravis.
To study the Sheiner model in a myasthenic situation and to validate the proposed pharmacokinetic–pharmacodynamic model, we developed a pig myasthenic model and conducted a pharmacokinetic–pharmacodynamic modeling study.
Materials and Methods
Following approval of the Ethical Committee on Animal Experiments of the University of Groningen (Groningen, The Netherlands), 16 female pigs (Yorkshire F1 hybrid; body weight, 25–30 kg) were studied. They were divided in two groups: one control group and one myasthenic group.
Induction of Myasthenia Gravis
In the myasthenic group, pigs were injected intramuscularly on day 1 with 100 μg Torpedo AChR (tAChR), emulsified in Specol (id-dlo, Lelystad, The Netherlands). Three weeks after primary immunization, pigs were boosted with 100 μg tAChR, again emulsified in Specol. tAChR was prepared by purifying AChR from electric organs of Torpedo californica (Pacific Biomarine, Venice, CA) by affinity chromatography using Cobra toxin coupled to sepharose 4B (Pharmacia LKB, Woerden, The Netherlands). 9
The diagnosis of myasthenia gravis was made based on bending off of the growth curve, together with signs of muscular weakness. Pigs with myasthenia gravis lay down, or were only able to stand upright for a very short time. To objectify the degree of myasthenia gravis, a train-of-four (TOF) ratio was determined before the administration of rocuronium during the experiment under anesthesia (see Experimental Protocol). We diagnosed myasthenia gravis in the pigs without delay, by checking the pig's health and appetite every day after the second injection. If the pig had signs of myasthenia gravis and it was not possible to conduct the experiment immediately, the pig was temporarily treated with intramuscular pyridostigmine administered at 4-h intervals.
After a fasting period of 16 h with free access to water, the pigs were anesthetized with 500 mg ketamine followed by 15 mg midazolam, given intramuscularly. Pigs were weighed, and an ear vein was cannulated to allow infusions of pentobarbital (2 mg · kg−1 · h−1). Fentanyl bolus doses were given if needed (2–4 μg/kg). The trachea was intubated, and the lungs were artificially ventilated with an air–oxygen mixture, using a Cameco UV 705 respirator (Cameco, Sweden), with a frequency of 19 breaths/min, and 20 cm water pressure. The end-tidal carbon dioxide level was maintained between 4 and 5 kPa (Godart Capnograph Mark 11; E. Jaeger, Wuerzburg, Germany). Heart rate and blood pressure were measured continuously (Pressure Transducer, HP 78342A; Hewlett Packard, Boeblingen, Germany). Rectal temperature was measured continuously, and the temperature of the pig was maintained at 38°C with a heating blanket. The jugular vein was cannulated for infusion of fluids (2.5% glucose in 0.45% saline) and drugs (pentobarbital, fentanyl, and rocuronium). The left axillary artery was catheterized for continuous blood pressure measurements and for sampling of blood. The common peroneal nerve was exposed left and right and attached to two silver stimulation electrodes. To prevent repetitive backfiring, the nerve was ligated proximal to the electrodes. The overlying skin was closed, and the left nerve was stimulated supramaximally with square wave stimuli of 0.2 ms at a frequency of 0.1 Hz (Grass S88; Grass Instruments, Quincy, MA). The response of the left tibialis anterior muscle was registered mechanomyographically using a force transducer (LB 8000 25N; Maryland Instruments Corp., Baltimore, MD) connected to a muscle relaxation monitor MK11 and to a recorder (MT 9000; Astro-Med, West Warwick, RI). Preload was measured continuously and kept constant at approximately 75 g. The right nerve was stimulated every 15 s supramaximally with square wave TOF stimuli of 1 mA, with a duration of 0.2 ms at a frequency of 2 Hz. The muscle response was allowed to stabilize before starting an infusion with rocuronium. Before the rocuronium infusion, a blood sample was drawn for determination of circulating antibodies against the AChR (see Immunohistochemistry).
Each pig received an infusion with a muscle relaxant. After stabilization of the twitch, myasthenic pigs received an infusion of 25 μg · kg−1 · min−1 rocuronium, until there was an 80% twitch depression. The infusion was then stopped. Control pigs received an infusion of rocuronium at a rate of 116.7 μg · kg−1 · min−1 after stabilization of the twitch. The twitch height and TOF ratio (the ratio between the fourth and the first twitch response during TOF stimulation) were recorded continuously.
During onset of block and at maximal block, arterial samples of 2 ml were taken each minute. During recovery, samples were taken at 20, 40, 60, and 80% twitch height recovery Additional samples were taken regularly until an hour after the start of the rocuronium infusion. Blood was collected into lithium-heparin–coated tubes, stored at room temperature, and centrifuged for 10 min at 4,000 g within an hour after taking the sample. Rocuronium has been shown to be stable in plasma at room temperature. The plasma was collected and stored at −20°C until analysis was done.
At the end of the experiments, the anterior tibial muscles were removed from all the pigs and stored at −80°C. Pigs were then terminated by an overdose of pentobarbital.
Determination of Rocuronium in Plasma
Determination of rocuronium in plasma was carried out by high-performance liquid chromatography using post column ion-pair extraction and fluorometric determination. 10
The method showed a linear relationship between the logarithm of the amount of rocuronium and the logarithm of the response ratio in a range of at least 10–1,000 ng. The mean precision, expressed in the coefficients of variation of the intraday variability and of the accuracy data, was 6%, whereby 200–1,000 μl plasma can be processed. The mean absolute deviation of the accuracy samples covering the concentration of the unknown samples was 5%. The lower limit of quantization, defined as the minimum concentration that could be detected with a precision and accuracy better than 15%, was 10 ng/ml. The lower limit of detection, the amount of rocuronium resulting in a signal-to-noise ratio of 5, was estimated to be 3 ng.
Plasma concentration–time data were analyzed by iterative Bayesian two-stage analysis 11
and using the program Multifit (Johannes H. Proost, Pharm.D., Ph.D., Department of Anesthesiology, University Hospital Groningen, Groningen, The Netherlands). Mean values and SDs of the pharmacokinetic population parameters of a one-compartment model (CL, V1
), a two-compartment model (CL10
), and a three-compartment model (CL10
) and the residual variance were estimated by an iterative Bayesian procedure using the plasma concentration–time data of each examined pig. A log-normal distribution for both the pharmacokinetic population parameters and the plasma concentration measurement errors was assumed. The correctness of the latter assumption was tested by visual inspection of the graphs of the residuals plotted against time and against concentration. Goodness of fit was evaluated from visual inspection of the measured and calculated data points and of the residuals plotted against time and against concentration. The choice between a one-, two-, and three-compartment model was based on the Akaike Information Criterion (AIC). 12
The AIC was calculated as −2 times the sum of the log likelihood of all individual animals within the group and increased by a value of 2 for each variable parameter. The groups of myasthenic and control pigs were fitted separately.
Two pharmacokinetic–pharmacodynamic models were applied to the data. First, the Sheiner model, with an effect compartment linked to the plasma compartment, was applied to the data using the actual plasma concentration data. 13
Second, we applied a new link model, which takes into account the number of the free AChR concentration, the unbound receptor model (see Appendix
). The twitch height–time data were analyzed by an iterative Bayesian two-stage analysis using the program PkPdFit (written by Johannes H. Proost, Pharm.D., Ph.D.). The goodness of the fit was evaluated by visual inspection of the measured and calculated data, by the degree of minimization of the hysteresis loop, by the residual SD, and by the AIC value. The groups of myasthenic and control pigs were fitted separately. The molecular weight of rocuronium is 609.69.
Determination of AChR
The concentration of AChR was determined in anterior tibial muscles of control pigs and myasthenic pigs as described previously, 14
with minor modifications. Briefly, frozen tissue was homogenized, and AChR was extracted with 2% Triton X-100 (Sigma, Brunschwig Chemie b.v., Amsterdam, The Netherlands). An aliquot of 500 μl of each extract was labeled with 125
I-α-bungarotoxin (74 TBq/mmol; Amersham Pharmacia Biotech UK Limited, Little Chalfont, United Kingdom), incubated overnight with excess rat anti-AChR IgG (MAb35) and precipitated by goat antirat antibodies. Radioactivity was measured in a γ counter.
Muscle biopsy cryosections (thickness, 8 μm) of anterior tibial muscle of myasthenic and control pigs were acetone-fixed for 10 min at −20°C and air-dried for 5 min. The sections were preincubated in PBS containing 2% bovine albumin serum and 2% normal rabbit serum and subsequently incubated with plasma from pigs who developed clinical signs of myasthenia gravis, together with rhodamine-labeled α-bungarotoxin (Molecular Probes, Eugene, OR) overnight at 4°C to colocalize AChR in the same section. After being washed three times with PBS, the sections were incubated for an hour with FITC-labeled rabbit antiswine IgG antibodies.
Differences between myasthenic and control pigs were tested with the Mann–Whitney U test; statistical significance was assumed if P
was smaller than 0.05. The interval 25–75% was defined as the time elapsed between 25% twitch height and 75% twitch height. The AIC was used for comparison between two pharmacokinetic–pharmacodynamic models; a lower value of the AIC represents a better fit. 12
We induced myasthenia gravis in eight pigs. All pigs became myasthenic, six pigs became myasthenic between 7 and 9 days after the second injection with tAChR, one pig needed three injections with tAChR before it became myasthenic, and one pig became myasthenic 1 week after the first injection. Most pigs showed, apart from signs of muscular weakness, bending in their weight gain after the second injection with tAChR.
The baseline TOF ratio, which was measured before rocuronium administration, was less than 90% in all myasthenic pigs, and the dose of rocuronium needed to obtain a block between 80–90% twitch height depression was reduced by 83% compared to control pigs. There was a significant difference between intervals 25–75% (P
< 0.0005) between myasthenic pigs and control pigs (table 1
For each group, the plasma concentration–time data of all pigs were included in an iterative Bayesian two-stage analysis. According to the AIC, a three-compartment model did not fit significantly better than a two-compartment model. The AIC values were for myasthenic pigs 255, 97, and 128 and for control pigs 327, −153, and −148 for one-, two- and three-compartment models, respectively. The results of the analysis are summarized in table 2
The time course of effect of the neuromuscular block is depicted in figure 1
, both for control pigs (A) and myasthenic pigs (B).
The results of the fitting procedure with the unbound receptor model are presented in table 3
. The AIC after the fitting procedure with the unbound receptor model was 3,605 versus
3,769 with the Sheiner model, the residual SD being 3.16 versus
3.58%, respectively. This better fit with the unbound receptor model arises from a better performance at profound block and late recovery than the Sheiner model for myasthenic pigs. An example of how this model improves fitting is shown by figure 2
. Both models performed almost equally well for control pigs with an AIC of 2,334 versus
2,323 and a residual SD of 2.66 versus
2.62% for the unbound receptor model and Sheiner model, respectively. There was no significant difference between the EC50
derived with the Sheiner model or the unbound receptor model, both for control pigs and myasthenic pigs. In tables 3 and 4
, the results of the fitting procedure with the unbound receptor model and the link model proposed by Sheiner, respectively, are summarized.
The unbound receptor model calculates an AChR concentration of 0.27 μm in myasthenic pigs and an AChR concentration of 1.47 μm in control pigs. This equals a decrease in AChR of 81% compared to control pigs. Using the in vitro radioactive immunoassay, we found a decrease in AChR concentration in myasthenic pigs of 76% compared to control pigs.
The serum of all myasthenic pigs contains antibodies directed against the neuromuscular junction, as shown by the indirect immunofluorescence assay (fig. 3
We developed an animal myasthenia gravis model that enabled us to study the time course of effect of NMBAs in vivo
. We preferred to develop a pig model because it would allow us to draw a substantial number of arterial samples to determine the concentration of rocuronium in plasma over time. Furthermore, over time, a large number of pharmacokinetic–pharmacodynamic data about rocuronium in pigs is available 15,16
for comparison. 17
We also choose the pig as the animal species because it is an omnivore in which pharmacokinetic behavior of rocuronium may more closely resemble this behavior in humans.
For the first time, a reproducible myasthenia gravis model in pigs has been established since all immunized pigs developed clinical signs of myasthenia gravis. The pigs showed a decreased need for rocuronium and the control TOF ratio was decreased to 58%, before the start of rocuronium administration. A decrement is also seen in humans with myasthenia gravis before the start of relaxant infusion, 18–20
although to some lesser extent. Our myasthenic pigs were more severely myasthenic than patients who undergo surgery after treatment of their myasthenic condition by plasmapheresis or immunosuppressant drugs. There seems to be some heterogeneity in the disease state of these myasthenic pigs as observed clinically and as measured by AChR loss; some are more affected by the disease than others. Probably, the immune response to the tAChR injection is quantitatively different among different pigs. This heterogeneity has been described earlier for humans 21
and rats. 22
The intervals 25–75% (table 1
) in myasthenic pigs are significantly longer than those of control pigs, which can be understood from the myasthenic disease which leads to less AChR at the neuromuscular junction. This means that the safety margin is decreased. In our opinion, the unbound receptor model may predict this prolonged recovery more adequately, based on receptor concentration, than the Sheiner model, based on a different γ.
The pharmacokinetic modeling revealed that the pharmacokinetic parameters did not differ widely between both groups, which could be expected because myasthenia gravis only affects the neuromuscular junction. Although the circulating volume may be decreased in the myasthenic pigs since the myasthenic state prevents the animal to maintain its normal food and water intake, nevertheless, from the kinetic analysis, it is clear that this does not influence the kinetic parameters to a large extent because we started the experimental procedure shortly after the occurrence of myasthenic weakness in the pigs.
The use of a pharmacokinetic–pharmacodynamic model that takes the number of unbound (free) receptors into account improves pharmacokinetic–pharmacodynamic modeling of the concentration–effect relationship of rocuronium in myasthenic pigs when compared to the link model proposed by Sheiner. 5
The most relevant advance of the unbound receptor model over the Sheiner model is that the unbound receptor model is designed to give a more physiologic explanation of the observed changes in the time course of effect. We chose to model the unbound receptor concentration because it is well known that different effects cause the diminishing of functional AChR at the neuromuscular junction of myasthenic animals. Antibodies against AChR interfere with the neuromuscular junction in three ways. 23
First, the antibodies against the AChR accelerate the rate of degradation of the receptor, resulting in a decrease of AChR at the neuromuscular junction. A second mechanism is activation of the complement that causes destruction of the postsynaptic membrane by a lytic membrane attack complex (this also decreases the AChR concentration). The third mechanism is the direct blockade of the AChR by the antibodies that bind to the AChR, which causes allosteric inhibition of the receptor function, the antibody being many times as large as an ACh molecule or an NMBA. 2
The Sheiner model shows a decreased EC50 in myasthenic pigs (0.27 vs. 2.8 μm in control pigs) and a decreased γ in myasthenic animals (1.70 vs. 2.87 in control animals). Both the EC50 and γ differ significantly between myasthenic animals and the control group. The lower EC50 reflects the increased sensitivity to rocuronium in myasthenic pigs (and patients), while the lower γ reflects the prolonged duration of neuromuscular block. The Sheiner model describes the observed differences in the time course of myasthenic pigs by a lower EC50 and γ, but it does not provide an explanation to why these values would be lower. The unbound receptor model calculates a significantly decreased receptor concentration in myasthenic pigs (Rtot, 0.27 vs. 1.47 μm in control animals). This decreased receptor concentration leads to the increased sensitivity to NMBAs and thus the lower EC50. The decrease in receptor concentration, calculated by the unbound receptor model, is in agreement with the decrease we measured during the radioimmunoassay. This observation supports the explanatory value of the unbound receptor model. There is no significant difference in β between myasthenic and control pigs. This is because the unbound receptor model explains the observed differences in potency and time course of effect of NMBAs from the decrease in receptor concentration in myasthenic pigs, without the need for a change in the steepness of the concentration-versus-effect relationship (β).
The Sheiner model contains three parameters, which can be assessed reliably. The unbound receptor model contains five parameters. These five parameters could not be uniquely identified, indicating that the model is overparameterized in relation to the available data. Therefore, we estimated two parameters in a different way and used these estimates as fixed parameters. Kd was estimated from the observed mean EC50 in control pigs and the assumption that in control pigs, receptor occupancy is 87.5% at 50% neuromuscular block. The parameter Kd in the unbound receptor model is the dissociation constant of the rocuronium-receptor complex. Since it is likely that receptors are the same in all normal pigs, it follows that the value of Kd is the same in all normal pigs. In myasthenic pigs, part of the AChRs is blocked by antibodies or internalized. There is no a priori reason why the remaining functional receptors would be different, for the very reason that they are functional. In the unbound receptor model, Rtot reflects these functional receptors only. Similarly, we assumed that Rfree50 was the same in all pigs.
To investigate the implications of the assumption of 87.5% receptor occupancy at 50% in control pigs on the presented results, we repeated the analysis with other values for this assumption. Assuming that 50% block is reached at 75% receptor occupancy in control pigs, Kd is increased by a factor 7/3 to 0.94 μm. An Rfree50 value of 0.63 μm was obtained by minimizing of the AIC during fitting of the animals of both groups simultaneously. After fitting of the groups separately, the values of ke0 were only slightly affected, and median β was increased from 2.63 to 4.22 in myasthenic pigs and from 2.84 to 3.29 in control pigs, but median Rtot markedly increased from 0.27 to 0.72 μm in myasthenic pigs, and from 1.47 to 2.42 μm in control pigs. The ratio between the median values of both groups was moderately affected, from 0.19 in the original analysis to 0.29 for a Kd value of 0.94 μm. Both values agree reasonably well with the decrease of 76% obtained from the radioimmunoassay. From this analysis, it can be concluded that the absolute values of Rtot are indeed dependent on the values for Kd and Rfree50, but the conclusions of the study are not markedly affected by the assumptions with respect to receptor occupancy at 50% block.
We did a pharmacokinetic–pharmacodynamic simulation of the time course of effect of an ED90
infusion of rocuronium with the data obtained in this study (fig. 4
). We used the median pharmacokinetic and pharmacodynamic values of control pigs (control) and myasthenic pigs (myasthenic) (tables 2 and 3
). We also used the results of the control pigs and only reduced the receptor concentration from 1.47 μm to 0.27 μm to show the effect of receptor concentration (myasthenic simulation).
The figure shows that the receptor concentration has little influence on the interval 75–25% during onset (1.3 min in control pigs vs. 1.5 min in the myasthenic simulation vs. 1.8 min in myasthenic pigs), but the interval 25–75% during recovery is increased in the myasthenic simulation (5.3 min) and in myasthenic pigs (8.3 min) compared to controls (2.5 min). The myasthenic simulation predicts not exactly the measured interval 25–75% we measured in myasthenic pigs, but in the myasthenic pigs, the ke0 was different from the ke0 of control pigs, which may explain the difference between the simulation and the results in the in vivo pig. This may probably be related to the existence of a relatively hypovolemic state in these myasthenic animals, resulting in a diminution of the cardiac output and consequently in a smaller value of the rate of equilibration ke0. This assumption is supported by the observation that the initial volume of distribution is lower in six out of eight myasthenic pigs compared to control pigs.
As far as we know, this is the first study on pharmacokinetic–pharmacodynamic modeling of NMBAs in a myasthenic situation. There have been dose–response studies 19,24,25
; case reports about the use of NMBAs in myasthenic patients, 8,26–30
which have in common that the effective dose of a nondepolarizing NMBA is decreased; and reviews with advice for anesthetic management in myasthenic patients. 31,32
We conclude that the unbound receptor pharmacokinetic–pharmacodynamic model explains the observed changes in the time course of effect of rocuronium in the myasthenic pig on a more physiologic base than the Sheiner model. Further studies to validate the model in myasthenic patients will need to be conducted.
The authors thank Barbie Machiels, Ph.D. (Research Analyst, Department of Psychiatry and Neuropsychology, Section Basal Neurosciences, University of Maastricht, Maastricht, The Netherlands), and Ageeth Knol, B.Sc. (Research Analyst, Department of Oncology, University Hospital Groningen, Groningen, The Netherlands), for laboratory assistance.
Appendix: Unbound Receptor Model
The existing pharmacokinetic–pharmacodynamic models assume that the neuromuscular blocking effect is related to the (unbound) concentration of the drug in the effect compartment, i.e.
, the neuromuscular junction. 5,6
However, this assumption makes no sense from a mechanistic point of view because the effect is the result of binding of the NMBA to the receptor, and not just of the presence of free drug in the biophase. Alternatively, one might relate the effect to the concentration of bound NMBA. This hardly affects the model in a qualitative way since the unbound concentration and the bound concentration are strongly correlated.
NMBAs are antagonists of acetylcholine, which is in turn responsible for neuromuscular transmission. Therefore, we postulated that the contractile force of a muscle after supramaximal stimulation, measured as twitch height (TH), is related to the free AChR concentration according to the sigmoid Emax model (Hill equation): where THmax = maximum twitch height, i.e., TH in case the number of free receptors is infinitely high; Rfree = concentration of free receptors; Rfree50 = concentration of free receptors at which TH is 50% of THmax; and β = exponential coefficient.
In the absence of NMBA, the concentration of free receptors equals the total receptor concentration; on substitution in equation 1
, it follows: where THc
= twitch height in the absence of NMBA, and Rtot
= total receptor concentration.
The neuromuscular blocking effect of an NMBA is defined as:
describes the neuromuscular blocking effect as a function of the free AChR concentration. Rtot
, and β are model parameters.
Binding of the NMBA to the AChR binding sites is characterized by the equilibrium dissociation constant of the drug-receptor complex (Kd
= unbound concentration of NMBA in the effect compartment, Rfree
= concentration of free binding sites of AChR, and Rbound
= concentration of AChR receptor sites to which an NMBA molecule is bound.
Defining Rtot as the total concentration of AChR binding sites, it follows upon rearrangement:
The time course of the unbound concentration in the effect compartment can be evaluated as described earlier. 7
Equation 16 of that article was simplified, assuming Cu = C (fu = 1), fue
= 1, kue
, and Pue
= 1, resulting in:MATH
where Cu is the unbound relaxant concentration in plasma compartment, C is the concentration in plasma compartment, fu is the fraction unbound relaxant in plasma compartment, fue
is the fraction unbound relaxant in effect compartment, kue
is the transport rate constant, and Pue
is the ratio between unbound concentration of relaxant in plasma compartment and effect compartment during steady state.
Fitting of each of the model parameters (ke0
, and β) did not result in reliable parameter estimates due to the strong correlation between the parameters, in particular between Kd
, and Rfree50
. Since the aim of the study was to investigate the influence of the AChR concentration (Rtot
) on the potency and time course of effect, this parameter was assumed to be variable between the animals. In contrast, the values for Kd
were assumed to be the same for each animal. Estimates for these values were obtained as follows: Assuming that a neuromuscular block of 50% is reached at a receptor occupancy of 87.5% in case of a normal AChR density (i.e.
, in controls), the value of Rfree
at 50% block is 12.5% of the normal total receptor concentration. 33
Using the Sheiner model, the median EC50
in control animals was 2.83 μm. On substitution of this value of EC50
in equation 6
, and Rfree
= 0.125, it follows that Kd
= 0.40 μm. This value was used for each animal of both groups. A value of Rfree50
of 0.19 μm was estimated by minimization of the AIC during fitting of the animals of both groups simultaneously. Cited Here...
1. Martyn JA, White DA, Gronert GA, Jaffe RS, Ward JM: Up-and-down regulation of skeletal muscle acetylcholine receptors: Effects on neuromuscular blockers. A nesthesiology 1992; 76: 822–43
2. Jahn K, Franke C, Bufler J: Mechanism of block of nicotinic acetylcholine receptor channels by purified IgG from seropositive patients with myasthenia gravis. Neurology 2000; 54: 474–9
3. Paterson IG, Hood JR, Russell SH, Weston MD, Hirsch NP: Mivacurium in the myasthenic patient. Br J Anaesth 1994; 73: 494–8
4. Baraka A, Haroun-Bizri S, Kawas N, Hajjar AM, Kawkabani N: Rocuronium in the myasthenic patient (letter to the editor). Anaesthesia 1995; 50: 1007
5. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J: Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine. Clin Pharmacol Ther 1979; 25: 358–71
6. Donati F, Meistelman C: A kinetic-dynamic model to explain the relationship between high potency and slow onset time for neuromuscular blocking drugs. J Pharmacokinet Biopharm 1991; 19: 537–52
7. Proost JH, Wierda JM, Meijer DK: An extended pharmacokinetic/pharmacodynamic model describing quantitatively the influence of plasma protein binding, tissue binding, and receptor binding on the potency and time course of action of drugs. J Pharmacokinet Biopharm 1996; 24: 45–77
8. Hunter JM, Bell CF, Florence AM, Jones RS, Utting JE: Vecuronium in the myasthenic patient. Anaesthesia 1985; 40: 848–53
9. Lindstrom J, Anholt R, Einarson B, Engel A, Osame M, Montal M: Purification of acetylcholine receptors, reconstitution into lipid vesicles, and study of agonist-induced cation channel regulation. J Biol Chem 1980; 255: 8340–50
10. Kleef UW, Proost JH, Roggeveld J, Wierda JM: Determination of rocuronium and its putative metabolites in body fluids and tissue homogenates. J Chromatogr 1993; 621: 65–76
11. Mentre F, Gomeni R: A two-step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmacokinetics. J Biopharm Stat 1995; 5: 141–58
12. Yamaoka K, Nakagawa T, Uno T: Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978; 6: 165–75
13. Unadkat JD, Bartha F, Sheiner LB: Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models. Clin Pharmacol Ther 1986; 40: 86–93
14. Amaki Y, Waud BE, Waud DR: Atracurium-receptor kinetics: Simple behavior from a mixture. Anesth Analg 1985; 64: 777–80
15. Lindstrom JM, Lennon VA, Seybold ME, Whittingham S: Experimental autoimmune myasthenia gravis and myasthenia gravis: Biochemical and immunochemical aspects. Ann N Y Acad Sci 1976; 274: 254–74
16. Beaufort TM, Proost JH, Houwertjes MC, Roggeveld J, Wierda JM: The pulmonary first-pass uptake of five nondepolarizing muscle relaxants in the pig. A nesthesiology 1999; 90: 477–83
17. Gyermek L, Lee C, Nguyen N: Pharmacology of G-1-64, a new nondepolarizing neuromuscular blocking agent with rapid onset and short duration of action. Acta Anaesthesiol Scand 1999; 43: 651–7
18. Marshall RJ, Muir AW, Sleigh T, Savage DS: An overview of the pharmacology of rocuronium bromide in experimental animals. Eur J Anaesthesiol Suppl 1994; 9: 9–15
19. Nilsson E, Paloheimo M, Muller K, Heinonen J: Halothane-induced variability in the neuromuscular transmission of patients with myasthenia gravis. Acta Anaesthesiol Scand 1989; 33: 395–401
20. Nilsson E, Meretoja OA: Vecuronium dose-response and maintenance requirements in patients with myasthenia gravis. A nesthesiology 1990; 73: 28–32
21. Mann R, Blobner M, Jelen-Esserborn S, Busley R, Werner C: Preanesthetic train-of-four fade predicts the atracurium requirement of myasthenia gravis patients. A nesthesiology 2000; 93: 346–50
22. Compston DA, Vincent A, Newsom-Davis J, Batchelor JR: Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 1980; 103: 579–601
23. De Baets MH, Einarson B, Lindstrom JM, Weigle WO: Lymphocyte activation in experimental autoimmune myasthenia gravis. J Immunol 1982; 128: 2228–35
24. De Baets MH: Autoimmune diseases against cell surface receptors: Myasthenia gravis, a prototype anti-receptor disease. Neth J. Med 1994; 45: 294–301
25. Eisenkraft JB, Book WJ, Papatestas AE: Sensitivity to vecuronium in myasthenia gravis: A dose-response study. Can J Anaesth 1990; 37: 301–6
26. Smith CE, Donati F, Bevan DR: Cumulative dose-response curves for atracurium in patients with myasthenia gravis. Can J Anaesth 1989; 36: 402–6
27. Baraka A, Siddik S, Kawkabani N: Cisatracurium in a myasthenic patient undergoing thymectomy. Can J Anaesth 1999; 46: 779–82
28. Naguib M, Sari-Kouzel A, Ashour M, Seraj M, Messahel F: Myasthenia gravis and pipecuronium: Report of two cases. Middle East J Anesthesiol 1992; 11: 381–90
29. Ramsey FM, Smith GD: Clinical use of atracurium in myasthenia gravis: A case report. Can Anaesth Soc J 1985; 32: 642–5
30. Sanfilippo M, Fierro G, Cavalletti MV, Biancari F, Vilardi V: Rocuronium in two myasthenic patients undergoing thymectomy. Acta Anaesthesiol Scand 1997; 41: 1365–6
31. Seigne RD, Scott RP: Mivacurium chloride and myasthenia gravis. Br J Anaesth 1994; 72: 468–9
32. Baraka A: Anaesthesia and myasthenia gravis. Can J Anaesth 1992; 39: 476–86
33. Krucylak PE, Naunheim KS: Preoperative preparation and anesthetic management of patients with myasthenia gravis. Semin Thorac Cardiovasc Surg 1999; 11: 47–53
© 2003 American Society of Anesthesiologists, Inc.